Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

217 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pazopanib in advanced and platinum-resistant urothelial cancer: an open-label, single group, phase 2 trial.
Necchi A, Mariani L, Zaffaroni N, Schwartz LH, Giannatempo P, Crippa F, Morosi C, Lanocita R, Sava T, Ortega C, Messina C, Sacco C, Pennati M, Daidone MG, Nicolai N, De Braud F, Gianni AM, Salvioni R. Necchi A, et al. Among authors: sacco c. Lancet Oncol. 2012 Aug;13(8):810-6. doi: 10.1016/S1470-2045(12)70294-2. Epub 2012 Jul 20. Lancet Oncol. 2012. PMID: 22819172 Clinical Trial.
Analysis of plasma cytokines and angiogenic factors in patients with pretreated urothelial cancer receiving Pazopanib: the role of circulating interleukin-8 to enhance the prognostic accuracy.
Necchi A, Pennati M, Zaffaroni N, Landoni E, Giannatempo P, Raggi D, Schwartz LH, Morosi C, Crippa F, Farè E, Nicolai N, Lanocita R, Sava T, Sacco C, Messina C, Ortega C, De Braud FG, Salvioni R, Daidone MG, Gianni AM, Mariani L. Necchi A, et al. Among authors: sacco c. Br J Cancer. 2014 Jan 7;110(1):26-33. doi: 10.1038/bjc.2013.719. Epub 2013 Nov 14. Br J Cancer. 2014. PMID: 24231947 Free PMC article. Clinical Trial.
Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial.
Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S, Bologna A, Weber B, Raspagliesi F, Panici PB, Cormio G, Sorio R, Cavazzini MG, Ferrandina G, Breda E, Murgia V, Sacco C, Cinieri S, Salutari V, Ricci C, Pisano C, Greggi S, Lauria R, Lorusso D, Marchetti C, Selvaggi L, Signoriello S, Piccirillo MC, Di Maio M, Perrone F; Multicentre Italian Trials in Ovarian cancer (MITO-7); Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens et du sein (GINECO); Mario Negri Gynecologic Oncology (MaNGO); European Network of Gynaecological Oncological Trial Groups (ENGOT-OV-10); Gynecologic Cancer InterGroup (GCIG) Investigators. Pignata S, et al. Among authors: sacco c. Lancet Oncol. 2014 Apr;15(4):396-405. doi: 10.1016/S1470-2045(14)70049-X. Epub 2014 Feb 28. Lancet Oncol. 2014. PMID: 24582486 Clinical Trial.
Overall survival for sorafenib plus interleukin-2 compared with sorafenib alone in metastatic renal cell carcinoma (mRCC): final results of the ROSORC trial.
Procopio G, Verzoni E, Bracarda S, Ricci S, Sacco C, Ridolfi L, Porta C, Miceli R, Zilembo N, Bajetta E; Italian Trials in Medical Oncology (ITMO) group. Procopio G, et al. Among authors: sacco c. Ann Oncol. 2013 Dec;24(12):2967-71. doi: 10.1093/annonc/mdt375. Epub 2013 Sep 24. Ann Oncol. 2013. PMID: 24063860 Free article. Clinical Trial.
Clinical outcomes in patients receiving three lines of targeted therapy for metastatic renal cell carcinoma: results from a large patient cohort.
Iacovelli R, Cartenì G, Sternberg CN, Milella M, Santoni M, Di Lorenzo G, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Ruggeri EM, Berruti A, Cerbone L, Procopio G. Iacovelli R, et al. Among authors: sacco c. Eur J Cancer. 2013 Jun;49(9):2134-42. doi: 10.1016/j.ejca.2013.02.032. Epub 2013 Mar 18. Eur J Cancer. 2013. PMID: 23518211
Standard vs adapted sunitinib regimen in elderly patients with metastatic renal cell cancer: results from a large retrospective analysis.
De Giorgi U, Scarpi E, Sacco C, Aieta M, Lo Re G, Sava T, Masini C, De Vincenzo F, Baldazzi V, Camerini A, Fornarini G, Burattini L, Rosti G, Ferrari V, Moscetti L, Chiuri VE, Luzi Fedeli S, Amadori D, Basso U. De Giorgi U, et al. Among authors: sacco c. Clin Genitourin Cancer. 2014 Jun;12(3):182-9. doi: 10.1016/j.clgc.2013.11.005. Epub 2013 Nov 15. Clin Genitourin Cancer. 2014. PMID: 24369790
Second-line chemotherapy in recurrent clear cell ovarian cancer: results from the multicenter italian trials in ovarian cancer (MITO-9).
Esposito F, Cecere SC, Magazzino F, Katsaros D, Ottaiano A, Gadducci A, Pisano C, Scalone S, Rabaiotti E, Salutari V, Cormio G, Canuto EM, Greggi S, Savarese A, Marinaccio M, Scollo P, Santeufemia DA, Sacco C, Facchini G, Pignata S. Esposito F, et al. Among authors: sacco c. Oncology. 2014;86(5-6):351-8. doi: 10.1159/000358730. Epub 2014 Jun 12. Oncology. 2014. PMID: 24942520
Prognostic factors in patients receiving third line targeted therapy for metastatic renal cell carcinoma.
Iacovelli R, Farcomeni A, Sternberg CN, Cartenì G, Milella M, Santoni M, Cerbone L, Di Lorenzo G, Verzoni E, Ortega C, Sabbatini R, Ricotta R, Messina C, Lorusso V, Atzori F, De Vincenzo F, Sacco C, Boccardo F, Valduga F, Massari F, Baldazzi V, Cinieri S, Mosca A, Maria Ruggeri E, Berruti A, Procopio G. Iacovelli R, et al. Among authors: sacco c. J Urol. 2015 Jun;193(6):1905-10. doi: 10.1016/j.juro.2014.11.092. Epub 2014 Nov 26. J Urol. 2015. PMID: 25433306
217 results